Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

RWJ 67657, a potent, orally active inhibitor of p38 mitogen-activated protein kinase.

Wadsworth SA, Cavender DE, Beers SA, Lalan P, Schafer PH, Malloy EA, Wu W, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Wachter MP, Siekierka JJ.

J Pharmacol Exp Ther. 1999 Nov;291(2):680-7.

PMID:
10525088
2.

The development of novel and selective p56lck tyrosine kinase inhibitors.

Bullington JL, Cameron JC, Davis JE, Dodd JH, Harris CA, Henry JR, Pellegrino-Gensey JL, Rupert KC, Siekierka JJ.

Bioorg Med Chem Lett. 1998 Sep 22;8(18):2489-94.

PMID:
9873567
3.

6-Amino-2-(4-fluorophenyl)-4-methoxy-3- (4-pyridyl)-1H-pyrrolo[2, 3-b]pyridine (RWJ 68354): a potent and selective p38 kinase inhibitor.

Henry JR, Rupert KC, Dodd JH, Turchi IJ, Wadsworth SA, Cavender DE, Fahmy B, Olini GC, Davis JE, Pellegrino-Gensey JL, Schafer PH, Siekierka JJ.

J Med Chem. 1998 Oct 22;41(22):4196-8. No abstract available.

PMID:
9784093
4.

Nitroarylhydroxymethylphosphonic acids as inhibitors of CD45.

Beers SA, Malloy EA, Wu W, Wachter MP, Gunnia U, Cavender D, Harris C, Davis J, Brosius R, Pellegrino-Gensey JL, Siekierka J.

Bioorg Med Chem. 1997 Dec;5(12):2203-11.

PMID:
9459018
5.

Effect of carbohydrate modification on the localization of human polyclonal IgG at focal sites of bacterial infection.

Fischman AJ, Fucello AJ, Pellegrino-Gensey JL, Geltofsky J, Yarmush ML, Rubin RH, Strauss HW.

J Nucl Med. 1992 Jul;33(7):1378-82.

Supplemental Content

Loading ...
Support Center